{
    "brief_title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
    "phase": "Phase 1",
    "drugs": "['CT-0508', 'Pembrolizumab']",
    "drugs_list": [
        "CT-0508",
        "Pembrolizumab"
    ],
    "diseases": "['HER2-positive', 'Adenocarcinoma', 'Bile Duct Cancer', 'Biliary Tract Cancer', 'Bladder Cancer', 'Breast Cancer', 'Breast Neoplasm', 'Carcinoma, Ductal', 'Carcinoma, Hepatocellular', 'Cancer', 'Lung Cancer, Non-Small-Cell', 'Carcinoma, Ovarian Epithelial', 'Carcinoma, Small Cell', 'Carcinoma, Squamous', 'Carcinoma, Transitional Cell', 'Colorectal Cancer', 'Esophagogastric Junction Neoplasms', 'Inflammatory Breast Cancer', 'Stomach Neoplasms', 'Malignant Neoplasms', 'Ovarian Neoplasms', 'Pancreatic Cancer', 'HER2-positive Solid Tumors', 'HER2-positive Breast Cancer', 'HER2-positive Gastric Cancer', 'HER-2 Protein Overexpression', 'HER-2 Gene Amplification', 'Prostate Cancer', 'Head and Neck Cancer', 'Endometrial Cancer', 'Lung Cancer, Small Cell']",
    "diseases_list": [
        "HER2-positive",
        "Adenocarcinoma",
        "Bile Duct Cancer",
        "Biliary Tract Cancer",
        "Bladder Cancer",
        "Breast Cancer",
        "Breast Neoplasm",
        "Carcinoma",
        "Ductal",
        "Carcinoma",
        "Hepatocellular",
        "Cancer",
        "Lung Cancer",
        "Non-Small-Cell",
        "Carcinoma",
        "Ovarian Epithelial",
        "Carcinoma",
        "Small Cell",
        "Carcinoma",
        "Squamous",
        "Carcinoma",
        "Transitional Cell",
        "Colorectal Cancer",
        "Esophagogastric Junction Neoplasms",
        "Inflammatory Breast Cancer",
        "Stomach Neoplasms",
        "Malignant Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Cancer",
        "HER2-positive Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER-2 Protein Overexpression",
        "HER-2 Gene Amplification",
        "Prostate Cancer",
        "Head and Neck Cancer",
        "Endometrial Cancer",
        "Lung Cancer",
        "Small Cell"
    ],
    "enrollment": "48.0",
    "inclusion_criteria": "inclusion criteria: \n\n HER2-positive recurrent or metastatic solid tumors for which there are no available curative treatment options. \n\n Breast cancer and gastric/gastroesophageal junction cancers must have failed approved HER2-targeted agents. \n\n Other HER2-positive tumor types must have failed standard of care therapies, while prior therapy with anti-HER2 drugs is not required. \n\n Subject must be willing and able to undergo tumor tissue biopsy procedures \n\n Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 \n\n Subject has adequate bone marrow and organ function \n\n ",
    "exclusion_criteria": ": \n\n HIV, active hepatitis B or hepatitis C infection. \n\n Diagnosis of immunodeficiency or chronic exposure to systemic corticosteroid therapy or any other form of immunosuppressive therapy \n\n Untreated or symptomatic central nervous system (CNS) metastases or cytology proven carcinomatous meningitis. \n\n o Subjects with small, asymptomatic CNS metastases that do not require treatment are permitted to enroll. \n\n Left ventricular ejection fraction (LVEF) <50% as determined by ECHO or multiple gated acquisition scan (MUGA) \n\n Other protocol-defined Inclusion/Exclusion may apply. \n\n CT-0508 in Combination with Pembrolizumab Substudy Only: \n\n ",
    "brief_summary": "Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.",
    "NCT_ID": "NCT04660929"
}